Financhill
Buy
69

CAH Quote, Financials, Valuation and Earnings

Last price:
$154.42
Seasonality move :
0.45%
Day range:
$153.12 - $155.28
52-week range:
$93.17 - $156.44
Dividend yield:
1.31%
P/E ratio:
24.09x
P/S ratio:
0.17x
P/B ratio:
--
Volume:
2.8M
Avg. volume:
2.4M
1-year change:
58.06%
Market cap:
$36.9B
Revenue:
$226.8B
EPS (TTM):
$6.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CAH
Cardinal Health
$59.5B $2.13 1.61% 104.13% $156.74
BSX
Boston Scientific
$4.9B $0.70 18.78% 229.3% $116.96
BUDZ
Weed
-- -- -- -- --
COR
Cencora
$84.6B $3.83 8.14% 56.12% $317.23
MCK
McKesson
$104B $8.72 20.2% 18.43% $748.84
PNPL
Pineapple
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CAH
Cardinal Health
$154.44 $156.74 $36.9B 24.09x $0.51 1.31% 0.17x
BSX
Boston Scientific
$105.26 $116.96 $155.7B 76.83x $0.00 0% 8.93x
BUDZ
Weed
$0.03 -- $4.2M 180.00x $0.00 0% --
COR
Cencora
$291.24 $317.23 $56.4B 33.79x $0.55 0.74% 0.19x
MCK
McKesson
$719.51 $748.84 $89.9B 27.86x $0.71 0.38% 0.26x
PNPL
Pineapple
$0.1000 -- $7.3M -- $0.00 0% 49.15x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CAH
Cardinal Health
162.31% 0.200 22.64% 0.44x
BSX
Boston Scientific
33.49% 1.029 7.48% 0.68x
BUDZ
Weed
-- -1.086 -- --
COR
Cencora
88.58% 0.081 14.53% 0.48x
MCK
McKesson
157.93% 0.870 6.69% 0.51x
PNPL
Pineapple
-- 2.419 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CAH
Cardinal Health
$2.1B $656M 46.27% -- 1.35% $2.8B
BSX
Boston Scientific
$3.2B $937M 6.35% 9.57% 19.02% $277M
BUDZ
Weed
-- -$434.7K -- -- -- -$71.8K
COR
Cencora
$3.1B $1.2B 24.2% 183.42% 1.41% $3.2B
MCK
McKesson
$3.6B $1.7B 79.77% -- 1.72% $7.5B
PNPL
Pineapple
-- -- -- -- -- --

Cardinal Health vs. Competitors

  • Which has Higher Returns CAH or BSX?

    Boston Scientific has a net margin of 0.92% compared to Cardinal Health's net margin of 14.45%. Cardinal Health's return on equity of -- beat Boston Scientific's return on equity of 9.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    BSX
    Boston Scientific
    68.84% $0.45 $33.6B
  • What do Analysts Say About CAH or BSX?

    Cardinal Health has a consensus price target of $156.74, signalling upside risk potential of 1.49%. On the other hand Boston Scientific has an analysts' consensus of $116.96 which suggests that it could grow by 11.12%. Given that Boston Scientific has higher upside potential than Cardinal Health, analysts believe Boston Scientific is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    BSX
    Boston Scientific
    23 3 0
  • Is CAH or BSX More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

  • Which is a Better Dividend Stock CAH or BSX?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.31%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or BSX?

    Cardinal Health quarterly revenues are $54.9B, which are larger than Boston Scientific quarterly revenues of $4.7B. Cardinal Health's net income of $506M is lower than Boston Scientific's net income of $674M. Notably, Cardinal Health's price-to-earnings ratio is 24.09x while Boston Scientific's PE ratio is 76.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 8.93x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.17x 24.09x $54.9B $506M
    BSX
    Boston Scientific
    8.93x 76.83x $4.7B $674M
  • Which has Higher Returns CAH or BUDZ?

    Weed has a net margin of 0.92% compared to Cardinal Health's net margin of --. Cardinal Health's return on equity of -- beat Weed's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    BUDZ
    Weed
    -- -$0.00 --
  • What do Analysts Say About CAH or BUDZ?

    Cardinal Health has a consensus price target of $156.74, signalling upside risk potential of 1.49%. On the other hand Weed has an analysts' consensus of -- which suggests that it could fall by --. Given that Cardinal Health has higher upside potential than Weed, analysts believe Cardinal Health is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    BUDZ
    Weed
    0 0 0
  • Is CAH or BUDZ More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Weed has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.517%.

  • Which is a Better Dividend Stock CAH or BUDZ?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.31%. Weed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Weed pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or BUDZ?

    Cardinal Health quarterly revenues are $54.9B, which are larger than Weed quarterly revenues of --. Cardinal Health's net income of $506M is higher than Weed's net income of -$440.5K. Notably, Cardinal Health's price-to-earnings ratio is 24.09x while Weed's PE ratio is 180.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus -- for Weed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.17x 24.09x $54.9B $506M
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
  • Which has Higher Returns CAH or COR?

    Cencora has a net margin of 0.92% compared to Cardinal Health's net margin of 0.95%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 183.42%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    COR
    Cencora
    4.06% $3.68 $9B
  • What do Analysts Say About CAH or COR?

    Cardinal Health has a consensus price target of $156.74, signalling upside risk potential of 1.49%. On the other hand Cencora has an analysts' consensus of $317.23 which suggests that it could grow by 8.92%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    COR
    Cencora
    9 6 0
  • Is CAH or COR More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Cencora has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.596%.

  • Which is a Better Dividend Stock CAH or COR?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.31%. Cencora offers a yield of 0.74% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or COR?

    Cardinal Health quarterly revenues are $54.9B, which are smaller than Cencora quarterly revenues of $75.5B. Cardinal Health's net income of $506M is lower than Cencora's net income of $717.9M. Notably, Cardinal Health's price-to-earnings ratio is 24.09x while Cencora's PE ratio is 33.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 0.19x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.17x 24.09x $54.9B $506M
    COR
    Cencora
    0.19x 33.79x $75.5B $717.9M
  • Which has Higher Returns CAH or MCK?

    McKesson has a net margin of 0.92% compared to Cardinal Health's net margin of 1.39%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    MCK
    McKesson
    4.01% $10.01 $4B
  • What do Analysts Say About CAH or MCK?

    Cardinal Health has a consensus price target of $156.74, signalling upside risk potential of 1.49%. On the other hand McKesson has an analysts' consensus of $748.84 which suggests that it could grow by 4.08%. Given that McKesson has higher upside potential than Cardinal Health, analysts believe McKesson is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    MCK
    McKesson
    10 3 0
  • Is CAH or MCK More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison McKesson has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.469%.

  • Which is a Better Dividend Stock CAH or MCK?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.31%. McKesson offers a yield of 0.38% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or MCK?

    Cardinal Health quarterly revenues are $54.9B, which are smaller than McKesson quarterly revenues of $90.8B. Cardinal Health's net income of $506M is lower than McKesson's net income of $1.3B. Notably, Cardinal Health's price-to-earnings ratio is 24.09x while McKesson's PE ratio is 27.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.17x 24.09x $54.9B $506M
    MCK
    McKesson
    0.26x 27.86x $90.8B $1.3B
  • Which has Higher Returns CAH or PNPL?

    Pineapple has a net margin of 0.92% compared to Cardinal Health's net margin of --. Cardinal Health's return on equity of -- beat Pineapple's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
    PNPL
    Pineapple
    -- -- --
  • What do Analysts Say About CAH or PNPL?

    Cardinal Health has a consensus price target of $156.74, signalling upside risk potential of 1.49%. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Cardinal Health has higher upside potential than Pineapple, analysts believe Cardinal Health is more attractive than Pineapple.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    PNPL
    Pineapple
    0 0 0
  • Is CAH or PNPL More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Pineapple has a beta of 36.643, suggesting its more volatile than the S&P 500 by 3564.318%.

  • Which is a Better Dividend Stock CAH or PNPL?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.31%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or PNPL?

    Cardinal Health quarterly revenues are $54.9B, which are larger than Pineapple quarterly revenues of --. Cardinal Health's net income of $506M is higher than Pineapple's net income of --. Notably, Cardinal Health's price-to-earnings ratio is 24.09x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.17x versus 49.15x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.17x 24.09x $54.9B $506M
    PNPL
    Pineapple
    49.15x -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Best AI Index Fund to Buy
Best AI Index Fund to Buy

Over the last two years, companies with a focus on…

Where Will Salesforce Stock Be in 5 Years?
Where Will Salesforce Stock Be in 5 Years?

Salesforce (NYSE: CRM) just turned in a quarter that, on…

2 Ultra Safe Dividend Stocks to Buy Now
2 Ultra Safe Dividend Stocks to Buy Now

Historically, blue-chip dividend stocks have been good choices for periods…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
31
REGN alert for May 31

Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.

Buy
55
RGC alert for May 31

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Sell
42
AMBA alert for May 31

Ambarella [AMBA] is down 15.13% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock